A Phase I Pilot Trial of Immunotherapy With Autologous Tumor-Derived gp96 Heat Shock Protein - Peptide Complex (HSPPC-96) in Patients With Resected Pancreatic Adenocarcinoma
OBJECTIVES: I. Study the safety of autologous tumor derived gp96 heat shock protein peptide
complex (HSPPC-96) in patients with resected pancreatic adenocarcinoma. II. Examine the
immune response to HSPPC-96 in this group of patients.
OUTLINE: This is a dose escalation study. Six weeks after surgery patients are given
autologous tumor derived gp96 heat shock protein peptide complex (HSPPC-96) subcutaneously
once a week for 4 weeks. Five patients are initially enrolled at each of two dose levels. An
additional three patients may be enrolled at each dose level to determine the optimal dose
of HSPPC-96. Patients are followed at weeks 1, 4, and 12 after treatment.
PROJECTED ACCRUAL: A maximum of 16 patients will be accrued for this study.
Primary Purpose: Treatment
Jonathan Lewis, MD, PhD, FACS
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|